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Background: Nevirapine, an NNRTI used in HIV treatment, can cause hypersensitivity reactions in 6%–10% of
patients. In the most serious cases (1.3%) this can manifest as Stevens–Johnson syndrome (SJS) or toxic epider-
mal necrolysis (TEN).
Methods: DNA samples were obtained and analysed from a total of 209 adult patients with nevirapine hypersen-
sitivity (57 from a prospective cohort and 152 routine clinic patients) and compared with 463 control patients on
nevirapine without any hypersensitivity. The case group included 70 patients with SJS/TEN. All individuals were
genotyped for two SNPs in the CYP2B6 gene [c.516G.T (CYP2B6*9) and c.983T.C (CYP2B6*18)] using the TaqMan
real-time genotyping platform. The replication cohort comprised 29 controls and 55 nevirapine hypersensitive
patients, including 8 SJS/TEN cases.
Results: An association between the CYP2B6 c.983T.C polymorphism and nevirapine-induced SJS/TEN was
observed. In the SJS/TEN group, 30% of individuals possessed at least one c.983T.C versus 16% in the tolerant
group [P¼0.006; OR (95% CI) 2.24 (1.27–3.94)]. This association was not significant in the replication cohort
[P¼0.075; OR (95% CI) 4.33 (0.80–23.57)]. Combined analysis resulted in an OR of 2.52 (95% CI 1.48–4.20;
P¼0.0005) for the association of c.983T.C with SJS/TEN. No association was observed for c.983T.C with
other hypersensitivity phenotypes and for CYP2B6 c.516G.T with any hypersensitivity phenotypes.
Conclusions: Our data show an association between the c.983T.C polymorphism and nevirapine-induced
SJS/TEN. CYP2B6 c.983T.C has a frequency of 5%–10% in a variety of African populations, but is not observed
in Caucasians, thus representing an ethnic-specific predisposing factor.
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Introduction
Nevirapine is a potent NNRTI used in the treatment of HIV, now
largely used in developing countries. Individuals taking nevirapine
have a 6%–10% risk of developing a hypersensitivity reaction
(HSR).1,2 This can manifest clinically as hypersensitivity syndrome
(HSS) (fever, skin rash), severe blistering skin rashes, such as
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis
(TEN),3 and hepatotoxicity.4 The risk of nevirapine HSR is signifi-
cantly higher in individuals who start nevirapine at higher CD4+
cell counts (.400 cells/mm3 and .250 cells/mm3 for men and
women, respectively).5
Other drugs metabolized by P450 enzymes associated with
HSRs, including carbamazepine6 and abacavir,7 have shown
strong associations with human leucocyte antigen (HLA) alleles
in the major histocompatibility complex region of chromosome
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6. Nevirapine HSRs have also been linked with HLA alleles including
HLA-DRB1*0101,8,9HLA-Cw8,10 HLA-B*35:0511 and, most recently,
HLA-C*04:01,12 with the HLA predisposition for liver injury differ-
ent from that of skin injury.13 However, these associations are
not as strong as those observed with other drugs, such as abaca-
vir, and vary with both ethnicity and phenotype.
Nevirapine is mainly metabolized to 8-hydroxynevirapine by the
hepatic cytochrome P450 enzymes CYP2B6 and, to a lesser extent,
CYP3A4.14 Despite its extensive use in WHO-recommended regi-
mens in Africa, the effect of polymorphisms in genes encoding
nevirapine-metabolizing enzymes has not been extensively stud-
ied. CYP2B6 is characterized by wide inter-individual variability in
expression and activity in human livers.15,16 This variability is due,
in part, to the effects of genetic polymorphisms. One specific vari-
ant in exon 4 (c.516G.T), encoding a non-synonymous amino acid
substitution (p.G172H) (rs3745274) (CYP2B6*6/9), is associated
with a significant loss of function.15 – 18 Studies have shown that
the variant Tallele is associated with higher plasma concentrations
in adult populations of both Western European19 and sub-Saharan
African descent.20 Recently, c.516G.T was reported to be asso-
ciated with nevirapine-induced cutaneous adverse events in black
and white populations.13 This association was stronger when
the c.516G.T genotype was combined with carriage of the
HLA-Cw*04 allele.13 The c.516G.T polymorphism has also been
linked with nevirapine-induced neuropsychological toxicity,19 but
not with nevirapine-induced hepatotoxicity.13,21
Recent in vitro studies functionally characterizing CYP2B6
alleles showed that the CYP2B6*18 polymorphism defined by
c.983T.C (rs rs28399499) was enzymatically inactive,22 while
other polymorphisms (for example, c.516G.T) did demonstrate
some, albeit reduced, enzymatic activity. A small pharmacoki-
netic/pharmacogenetic sub-study in our Malawian cohort showed
that, whilst CYP2B6*18 had an effect on nevirapine plasma con-
centrations, there was no association between nevirapine plasma
concentrations per se and any hypersensitivity phenotype.23
However, an association has been demonstrated between
nevirapine-induced hepatotoxicity in a Mozambican cohort and
the c.983T.C polymorphism.24 The frequencies of both the
c.516G.T and c.983T.C polymorphisms can differ between dif-
ferent ethnicities. In particular, the c.983T.C is almost exclusively
found in populations of African ancestry.25
The primary objective of this study was to determine, in a large
patient cohort, whether c.516G.T and c.983T.C polymorphisms
are predisposing factors for nevirapine hypersensitivity in a
Malawian HIV-infected adult population. Secondly, we aimed to
investigate whether carriage of HLA-C*04:01 in combination with




Nevirapine-exposed hypersensitive cases and controls were recruited from
the outpatient clinic at the Queen Elizabeth Central Hospital between
March 2007 and December 2008 as previously described.12 Briefly, 1117
patients within the prospective study cohort were enrolled at the start of
the standard first-line ART regimen at the time (stavudine/lamivudine/
nevirapine) and followed for 6 months. Of these, 57 patients developed an
HSR as defined previously.12 Additionally a further 149 nevirapine
hypersensitive patients were recruited at the time of reaction from the
same centre separately to the prospective study and 28 were identified
retrospectively from patient records. Thus a total of 234 nevirapine hyper-
sensitive patients were identified. The hypersensitivity phenotypes and
total numbers are summarized as follows: (i) nevirapine-induced rash
(NIR) (n¼83), including patients with widespread maculopapular rash with-
out systemic manifestations and getting worse on treatment continuation;
(ii) HSS (n¼39), including patients with widespread rash and systemic man-
ifestations such as fever, cough or abnormal liver function tests; (iii) SJS
(n¼75), including extensive rash with the involvement of at least two
mucous membranes or blistering eruptions affecting,10% of the body sur-
face area; (iv) TEN (n¼4), including blistering rash affecting more than 30%
of the body surface area and mucous membrane involvement as per SJS26
(blistering of 10%–30% of the body surface area was termed overlap syn-
drome); and (v) drug-induced liver injury (DILI) (n¼36), manifesting with
clinically evident jaundice and abnormal ALT (.40 IU/L).
Three patients presented with both SJS/TEN and DILI. Causality assess-
ment was undertaken using the Naranjo causality assessment tool27,28
and reviewed independently by a dermatologist.
Controls were patients in the prospective cohort who had been on
nevirapine for at least 6 months without developing any features of
hypersensitivity.
Replication cohort
An additional 24 cases presenting with the hypersensitivity phenotype
according to the original criteria were identified retrospectively from the
Queen Elizabeth Central Hospital, Blantyre, Malawi, after the conclusion
of the initial recruitment phase (December 2008).
Thirty-two nevirapine hypersensitivity cases and 31 tolerant controls
were identified retrospectively in Uganda from the DART study cohort.29
Cases were defined according to available patient records and subse-
quently categorized into the sub-phenotypes previously described.
Ethics
The study received full ethics approval from the Liverpool School of Tropical
Medicine Research Ethics Committee (Liverpool, UK), the College of
Medicine Research and Ethics Committee, University of Malawi (Blantyre,
Malawi) and the Uganda National Council for Science and Technology. All
patients gave their written informed consent. All patients who met the cri-
teria for a case had nevirapine withdrawn in accordance with Malawian
National Treatment Guidelines. Local ethics approval was obtained for the
DART study as previously described29 with subsequent ethics approval for a
pharmacogenetic sub-study also obtained.30
DNA extraction and genotyping
DNA was extracted from whole blood using a salt precipitation protocol.31
Sufficient DNA was available from a total of 672/1294 (52%) individuals
in the discovery cohort (463 controls and 209 hypersensitivity cases). For
the replication cohort sufficient DNA was available from a total of 82/87
(94%) (29 controls and 53 cases). Genomic DNA was extracted from
5 mL of whole blood collected using the Oragene DNA Sampling kit
(DNAGenotek, Ontario, Canada) with the Chemagic Magnetic Module
(MSM) 1 system as per the manufacturer’s protocol (Chemagen
Biopolymer-Technologie AG, Baesweiler, Germany). All samples were geno-
typed for the c.516G.T and c.983T.C validated TaqMan Drug Metabolism
Genotyping Assays (Applied Biosystems, Foster City, CA, USA).
PCRs (5 mL) consisted of 1×Taqman Universal PCR master mix (Applied
Biosystems), 1× assay mix [unlabelled PCR primers and TaqMan minor
groove binding probes (FAMTM and VICw-labelled)] and 20 ng of DNA.
PCR was performed using an Applied Biosystems 7900HT real-time PCR
system (Applied Biosystems). The following cycling conditions were used:
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958C for 1 min followed by 40 cycles of 928C for 15 s and 608C for 1 min.
Allelic discrimination analysis and genotype calls were made with the ABI
7900HT Sequence Detection System (Applied Biosystems). Ten percent of
samples were duplicated in order to determine genotype concordance.
Genotype call rates of .95% and a Hardy–Weinberg equilibrium P value
.0.025 were also applied as cut-offs for both SNPs.
Statistical analysis
Statistical analysis was undertaken using SPSS 16.0 software, apart from
case–control analyses, which was carried out using Haploview 4.1
software (www.broad.mit.edu/mpg/haploview/). Association between
each non-genetic variable in turn (gender, age, BMI, CD4+ cell
count) and nevirapine-induced hypersensitivity risk was assessed using
binary logistic regression models. To test for association between each
nevirapine-induced hypersensitivity phenotype (all HSRs, NIR, HSS,
SJS/TEN, DILI) and each SNP in turn, two binary regression models were
fitted, The first (base model) included all non-genetic variables found
statistically significant in the univariate analyses (P,0.05). The second
(SNP model) was the same as the base model but also included a covariate
to represent the SNP of interest. An additive effect of the variant allele was
assumed. Homozygote wild-type was coded ‘0’, heterozygote ‘1’ and
homozygote variant allele ‘2’. For analysis of composite genotype (number
of c.516T and c.983C alleles), an additive effect was assumed and the
composite genotype coded according to the number of variant alleles
carried.
The likelihood ratio test was used to compare the base model with the
SNP model and thus determine whether association between the SNP and
outcome was statistically significant. Case–control comparison of allele
counts was also undertaken using a x2 test. For all analyses, both a
P value and the false discovery rate (FDR) were calculated.
Meta-analysis of our study data with previously published data was
undertaken using StatsDirect v2.6.8 (StatsDirect Ltd, Altrincham, UK)
using a random effects model.
Results
A total of 672 patients where DNA was available were genotyped
as the discovery cohort study. Demographic data for both nevira-
pine tolerant and intolerant patients are shown in Table 1.
Females accounted for 62.7% of the adverse event group
compared with 55.7% in the tolerant group, and no significant
association was found between gender and nevirapine-induced
hypersensitivity risk (P¼0.09). Further, mean age+SD (37.4+9.4
versus 36.2+9.8 years) and mean BMI+SD (21.0+4.0 versus
20.6+3.6 kg/m2) were not significantly different between the
adverse event and tolerant groups (P¼0.15). Mean CD4+ cell
count+SD in the adverse event group (294+208 cells/mm3) was
Table 1. Demographic and phenotypic data for the nevirapine discovery and replication cohorts
Discovery cohort (n¼672) Replication cohort (n¼82)
cases (n¼209) controls (n¼463) P value cases (n¼53) controls (n¼29) P value
Gender M: 78 (37%) M: 205 (44%) M: 22 (42%) M: 8 (28%)
F: 131 (63%) F: 258 (56%) 0.09 F: 31 (58%) F: 21 (72%) 0.005
Age (years), mean+SD 37.4+9.4 36.2+9.8 0.11 38.0+8.98 37.9+6.6 0.010
BMI (kg/m2), mean+SD 21.0+4.0 20.6+3.6 0.15 21.3+6.5 22.2+7.3 0.025
CD4+ count (cells/mm3), mean+SD 294+208 174+144 ,0.0001 145+125 79+54 0.002
M, male; F, female.
P values derived from binary logistic regression analysis.
Table 2. Association of CYP2B6 polymorphisms with nevirapine-induced HSR phenotypes in the discovery cohort
CYP2B6 c.516G.T CYP2B6 c.983T.C
n MAF P valuea
genotype frequency
P valueb n MAF P valuea
genotype frequency
P valuebGG GT TT TT TC CC
Tolerant 428 0.46 — 0.25 0.57 0.18 — 460 0.08 — 0.84 0.15 0.01 —
All HSRs 209 0.41 0.106 0.36 0.45 0.19 0.022 208 0.12 0.076 0.77 0.13 0.00 0.037
NIR 75 0.41 0.275 0.33 0.51 0.16 0.337 76 0.09 0.765 0.83 0.19 0.00 0.412
HSS 36 0.34 0.615 0.47 0.36 0.17 0.036 36 0.12 0.245 0.78 0.19 0.03 0.386
SJS/TENc 70 0.46 0.924 0.36 0.43 0.24 0.276 70 0.15 0.014 0.70 0.30 0.00 0.052
DILIc 30 0.35 0.094 0.43 0.43 0.13 0.301 29 0.07 0.673 0.86 0.14 0.00 0.047
MAF, minor allele frequency.
P values ,0.05 are shown in bold.
aP value from x2 test of association between allele count and phenotype.
bP value from likelihood ratio test comparing logistic regression models both with and without covariate representing SNP (adjusted for CD4+ cell count).
cThree patients presented with both SJS/TEN and DILI phenotypes.
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significantly higher than in the tolerant group (174+144 cells/mm3)
(P¼2.8×10213 in logistic regression analysis). Only CD4+ cell count
was therefore carried over as a covariate into the logistic regression
base model.
The phenotypes of the 209 nevirapine hypersensitive patients
included in the discovery cohort genotype analysis were categor-
ized as 76 NIR, 36 HSS, 67 SJS/TEN and 27 DILI with 3 of the
patients recorded as having SJS/TEN and DILI. Genotyping of
both polymorphisms (c.516G.T and c.983T.C) passed the pre-
determined call rate (95.1% for c.516G.T and 99.4% for
c.983T.C) and Hardy–Weinberg equilibrium P value (P¼0.059
for c.516G.T and 0.89 for c.983T.C) quality control thresholds.
The CYP2B6 genotype distributions and allele frequencies in the
study cohort (n¼672) are summarized in Table 2.
When undertaking x2 tests of association between allele
counts for each SNP and each nevirapine hypersensitivity pheno-
type in turn, no statistically significant associations were found
(FDR.0.05 for all analyses) (Table 2). Furthermore, there were
also no statistically significant associations in the logistic regres-
sion analyses (FDR.0.05 for all analyses) (Table 2). Case–control
analysis by logistic regression of a composite CYP2B6 genotype
based on the total number of minor alleles carried (Table 3) also
failed to show any significant associations with any of the hyper-
sensitivity phenotypes (FDR.0.05).
Since the association between c.983G.T and SJS/TEN was
the only significant observation where an increased frequency of
the functional minor allele was observed, an analysis of carriage
frequency incorporating a replication cohort was undertaken
(Table 4). In the discovery cohort, c.983C carriage was significantly
associated with SJS/TEN risk [P¼0.006, OR¼2.24 (95% CI 1.27–
3.94)]. The association was further strengthened when combined
with the replication cohort [P¼0.0005.OR¼2.52 (95% CI 1.48–
4.20); FDR¼0.015].
Meta-analysis of the c.983T.C polymorphism carriage and
SJS/TEN of our data and the only previous report that investigated
an association with nevirapine-induced SJS/TEN32 produced a
combined OR of 2.61 (95% CI 1.61–4.24) (data not shown).
Data relating to HLA-C allelotypes from our previous analysis12
was available for 124 controls and 32 SJS/TEN patients from the
discovery cohort. Carriage of both the HLA-C*04:01 and c.983T.C
allelic variants together was not significantly associated with SJS/
TEN (P¼0.16) with a frequency of co-occurrence of 0.12 in con-
trols and 0.21 in SJS-TEN.
Discussion
In this large study in Malawian and Ugandan adults treated with
nevirapine, we have been able to show an association between
nevirapine-induced SJS/TEN and the c.983T.C polymorphism.
The carriage frequency in nevirapine control individuals was
16% compared with 32% in those with nevirapine-induced SJS/
TEN (P¼0.0005, FDR¼0.015) (Table 4). This association was not
observed with any other nevirapine-induced hypersensitivity
phenotype.
The c.983T.C polymorphism is non-synonymous, encoding an
isoleucine to threonine amino change at codon 328 in exon 7.
Previous studies have suggested that the rs2839949 C allele is
present at a frequency of 4.4% in African–Americans and 6.6%
in a Ghanaian cohort, but is absent in Caucasians.33 In vitro
studies of the recombinant c.983C allele have demonstrated
undetectable levels of expression and enzymatic activity,33
while in vivo studies have shown that it acts as a determinant of
nevirapine plasma concentrations.34,35 It could be speculated
that the associated risk of SJS/TEN with the C allele is a result of
increased circulating parent compound or possibly biotransfor-
mation of nevirapine being pushed down an alternative pathway.
Table 3. Association of CYP2B6 composite genotype (total number of
c.516T and c.983C alleles) with nevirapine-induced HSR phenotypes in the
discovery cohort
n
Frequency of CYP2B6 minor allele carriage
(c.516G≥T and c.983T≥C)
P valuea0 alleles 1 allele 2 alleles 3 alleles
Tolerant 425 0.20 0.52 0.28 ,0.01 —
All HSRs 207 0.27 0.42 0.31 0.01 0.066
NIR 75 0.29 0.40 0.31 0.00 0.091
HSS 36 0.33 0.39 0.28 0.00 0.220
SJS/TENb 70 0.17 0.40 0.37 0.04 0.062
DILIb 29 0.38 0.41 0.21 0.00 0.244
aP value from likelihood ratio test comparing logistic regression models
both with and without covariate representing allele count (adjusted for
CD4+ cell count).
bThree patients presented with both SJS/TEN and DILI phenotypes.




P value OR (95% CI)n CYP2B6*18 carriage n CYP2B6*18 carriage
Discovery 460 74 (0.16) 70 21 (0.30) 0.006 2.24 (1.27–3.94)
Replication 29 3 (0.10) 8 4 (0.50) 0.075 4.33 (0.80–23.57)
Combined 489 77 (0.16) 78 25 (0.32) 0.0005a 2.52 (1.48–4.20)
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The c.516G.T polymorphism has previously been associated
with increased plasma nevirapine concentration in a number of
studies of patients of varied ethnicity19,34,36,37 as well as cutane-
ous adverse events in both white and black populations.13 Our
data appear to contradict this; however, it should be noted that
our data are derived mainly from a relatively homogeneous
Malawian population whilst previous studies described findings
in a self-reported black population where there was more ethnic
heterogeneity. Further investigation evaluating whether there is
any population stratification would be required to resolve this issue.
The CYP2B6*4 polymorphism (c.785A.G; rs2279343) that,
in combination with the c.516 G.T (CYP2B6*9) SNP, defines
the CYP2B6*6 allele was also analysed in our cohort (data
not shown). The CYP2B6 c.785A.G SNP was found to be in high
linkage disequilibrium (r2¼0.96) with the CYP2B6*9 defining
c.516G.T SNP and so it was felt likely that CYP2B6*6 (c.516T
and c.785G) would not be significantly associated with nevirapine
hypersensitivity (as per our findings for c.516G.T).
One interesting observation of this study is the identification of
three individuals (all SJS/TEN) who are homozygous for c.516Tand
heterozygous for c.983C and two individuals (both nevirapine tol-
erant) who are heterozygous for c.516G.T and homozygous for
c.983C (shown as carriers of 3 alleles in Table 3). Thus, all five
appear to carry a previously unreported haplotype whereby
c.516T and c.983C are carried on the same chromatid. However,
a lack of statistical power prevents any specific conclusions
being drawn as to whether the haplotype may be a significant
risk factor for SJS/TEN.
Within our patient group, CD4+ T cell count was a statistically
significant risk factor for nevirapine hypersensitivity (Table 1) with
the mean CD4+ T cell count being higher in patients experiencing
adverse events (294 versus 174 cells/mm3). This observation is
consistent with other studies that have described CD4+ cell
count as a risk factor for nevirapine-induced hypersensitivity.38
The implication from this is that, in an HIV patient treated with
nevirapine, a partially functioning immune system is needed to
mount an immune response. We have previously shown that
HLA-C*04:01 acts as a risk factor for nevirapine-induced SJS/TEN
consistent with the role of the immune response in the pathogen-
esis of nevirapine hypersensitivity. Here we found no significant
association between co-carriage of HLA-C*04: 01 and the
c.983T.C allele, and nevirapine-induced SJS/TEN, but this may
have been because of lack of power.
Previous studies in black African populations have demonstrated
that both the c.516G.T23,34 and c.983T.C polymorphisms affect
plasma nevirapine concentrations. Both polymorphisms have
been shown to be associated with hypersensitivity in a number of
studies. Although some evidence does exist,37– 40 there does not
seem to be a compelling direct functional association between
plasma concentrations and the risk of nevirapine hypersensitivity.
It is possible that local concentrations in the skin may be more
important. CYP2B6 is expressed in keratinocytes in particular within
the epidermis.41 Thus, in individuals with decreased functional
activity of CYP2B6, higher skin concentrations may be attained,
which could result in dermal immune activation. The lack of asso-
ciation with HSS may be a reflection of the lack of power, while the
lack of association with NIR may be due to the fact that causality is
more difficult to assess with the milder skin reactions.
A limitation of our study is the size of the replication cohort,
which was smaller than the discovery cohort and therefore lacked
the statistical power to truly replicate the association observed
between c.983T.C and nevirapine-induced SJS/TEN. However,
nevirapine hypersensitivity is a rare phenotype and it was difficult
to identify a larger number of patients. The replication cohort also
consisted of both Malawian and Ugandan patients, which may
introduce some population stratification. However, our data
show that the frequency of c.983T.C polymorphism in the overall
combined Malawian discovery and replication patients (0.18) was
comparable to that observed in the Ugandan patients (0.15), and
to that reported in a Mozambican population (0.14).32 Although
genetic differences do exist between these African cohorts, it
would appear from our study that CYP2B6 c.983T.C is likely to
be generalizable across other sub-Saharan-African populations.
In conclusion, our data suggest that the c.983T.C polymorph-
ism, but not c.516G.T, is a risk factor for nevirapine-induced SJS/
TEN in HIV-infected African adults from two different populations.
Further studies are needed to determine the role of metabolic
pathways in the predisposition to severe skin reactions, and how
this leads to immune activation locally within the skin.
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